Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 17:13:1036334.
doi: 10.3389/fphar.2022.1036334. eCollection 2022.

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations

Wenliang Liu  1 , Siying Ren  2 , Ying Xiao  2 , Lulu Yang  2 , Chao Zeng  1 , Yan Hu  1
Affiliations
Review

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations

Wenliang Liu et al. Front Pharmacol. .

Abstract

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) targeted therapy has become the standard of care for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC) on the basis of improved prognosis and reduced toxicities compared with chemotherapy. In view of the therapeutic potential of EGFR-TKIs in EGFR-mutated advanced NSCLC, several scholars have explored the value of preoperative use of EGFR-TKIs in patients with EGFR-mutated resectable NSCLC. However, the field of neoadjuvant targeted therapy for EGFR-mutated resectable NSCLC is currently in its infancy. In this mini-review, we summarize the current evidence on neoadjuvant EGFR-TKIs targeted therapy for resectable EGFR-mutated NSCLC and focus on discussing potential clinical strategies of treating resectable EGFR-mutated patients by preoperative administration of EGFR-TKIs-based multimodality therapy.

Keywords: CtDNA; EGFR; neoadjuvant targeted therapy; non-small cell lung cancer; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andrews Wright N. M., Goss G. D. (2019). Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl. Lung Cancer Res. 8 (3), S247–S264. 10.21037/tlcr.2019.06.01 - DOI - PMC - PubMed
    1. Blakely. C., Urisman A., Kerr D., Wu W., Bacaltos B., Rotow J., et al. (2021). P26.02 A phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutant non-small cell lung cancer: Updated results. J. Thorac. Oncol. 16 (10), S1039–S1040. 10.1016/j.jtho.2021.08.383 - DOI
    1. Cao Y., Geng J., Wang X., Meng Q., Xu S., Lang Y., et al. (2022). RNA-binding motif protein 10 represses tumor progression through the Wnt/β- catenin pathway in lung adenocarcinoma. Int. J. Biol. Sci. 18 (1), 124–139. 10.7150/ijbs.63598 - DOI - PMC - PubMed
    1. Chen W., Li P., Wang Q., Zhang Y., Li H., Jin X., et al. (2018). A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage IIIA EGFR-mutant lung adenocarcinoma. Chin. J. Oncol. 40 (2), 133–137. 10.3760/cma.j.issn.0253-3766.2018.02.010 - DOI - PubMed
    1. Duma N., Santana-Davila R., Molina J. R. (2019). Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 94 (8), 1623–1640. 10.1016/j.mayocp.2019.01.013 - DOI - PubMed